The study was funded by grants from the Department of Defense, the National Institutes of Health, the Skirball Foundation, National Alliance for Research on Schizophrenia and Depression, and the Swedish Royal Academy of Science.
Study co-authors also included Brian Alexander, Margarita Arango-Lievano, Mary Vernov, Mihaela Stavarache, from NewYork-Presbyterian Hospital/Weill Cornell Medical Center; Jennifer Warner Schmidt and Marc Flajolet, from Rockefeller University; Therese Eriksson and Per Svenningsson, from Karolinska Institute; Carol Tamminga and Subroto Ghose, from the University of Texas Southwestern Medical Center; and Sergei Musatov, from Neurologix Inc.
Dr. Kaplitt is a founder of and paid consultant for Neurologix Inc., which has licensed intellectual property rights to p11 gene therapy for behavioral disorders. Dr. Greengard is a founder of and equity holder in Intracellular Therapies Inc., which has licensed intellectual property rights to p11. Dr. Kaplitt and Dr. Alexander are inventors on a patent application assigned to Cornell University related to p11 gene therapy for behavioral disorders. Dr. Greengard and Dr. Svenningsson are inventors on a patent application assigned to the Rockefeller University related to the p11 gene and behavioral disorders.
For more information, patients may call (866) NYP-NEWS.
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
NewYork-Presbyterian Hospital/Weill Cornell Medical Center, located in New York City, is one of the leading academic medical centers in the world, comprising the teaching hospital NewYork-Presbyterian and Weill Cornell Medical College, the medical school of Cornell University. NewYork-Presbyterian/Weill Cornell provides state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine, and is committed to excellence in patient care, education, research and community service. Weill Cornell physician-scientists have been responsible for many medical advances -- including the development of the Pap test for cervical cancer; the synthesis of penicillin; the first successful embryo-biopsy pregnancy and birth in the U.S.; the first clinical trial for gene therapy for Parkinson's disease; the first indication of bone marrow's critical role in tumor growth; and, most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. NewYork-Presbyterian Hospital also comprises NewYork-Presbyterian Hospital/Columbia University Medical Center, NewYork-Presbyterian/Morgan Stanley Children's Hospital, NewYork-Presbyterian Hospital/Westchester Division and NewYork-Presbyterian/The Allen Hospital. NewYork-Presbyterian is the #1 hospital in the New York metropolitan area and is consistently ranked among the best academic medical institutions in the nation, according to U.S.News & World Report. Weill Cornell Medical College is the first U.S. medical college to offer a medical degree overseas and maintains a strong global presence in Austria, Brazil, Haiti, Tanzania, Turkey and Qatar. For more information, visit www.nyp.org and www.med.cornell.edu.
Gene therapy may be powerful new treatment for major depression
NewYork-Presbyterian/Weill Cornell paper reports that restoring a crucial gene in a tiny area of the brain reverses depression-like behavior in mice; human data back up the promise of such therapy
2010-10-21
(Press-News.org) NEW YORK (Oct. 20, 2010) -- In a report published in the Oct. 20 issue of Science Translational Medicine, researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center say animal and human data suggest gene therapy to the brain may be able to treat patients with major depression who do not respond to traditional drug treatment.
The researchers hope to rapidly translate their findings into a human clinical trial using the same kind of gene therapy modality the investigators have pioneered to treat Parkinson's disease. A 45-patient randomized blinded phase II multicenter clinical trial using the gene therapy to treat Parkinson's has recently ended and results are being readied for publication.
"Given our findings, we potentially have a novel therapy to target what we now believe is one root cause of human depression," says the study's senior investigator, Dr. Michael Kaplitt, associate professor and vice chairman for research of neurological surgery at Weill Cornell Medical College and a neurosurgeon at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
"Current therapies for depression treat symptoms but not underlying causes, and while that works for many patients, those with advanced depression, or depression that does not respond to medication, could hopefully benefit from our new approach," adds Dr. Kaplitt.
The Science Translational Medicine study demonstrates that a brain protein known as p11 in a single, small brain area, the nucleus accumbens, is critical to the feelings of reward and pleasure that are often missing in depression. This brain region had primarily been studied in addiction research, but the inability to find satisfaction with positive life experiences is one of the major sources of disability in depression.
While investigators believe that depression is a complex disorder that likely involves a number of brain areas and neural circuits, they say their findings suggest that restoring p11 may significantly alter the course of depression in humans.
"Applying molecular neurobiology and gene therapy to depression could dramatically alter the approach to psychiatric diseases," Dr. Kaplitt says. "Our results provide further evidence that the underlying causes of psychiatric disorders are due to molecular changes in key brain circuits, so that they are much more similar to common neurological disorders -- such as Parkinson's disease -- that might be helped by restoring molecular function."
The study pulls together human and animal data contributed by a team of researchers at NewYork-Presbyterian/Weill Cornell, as well as by investigators at Rockefeller University, Karolinska Institute in Sweden, the University of Texas Southwestern Medical Center and Neurologix in Fort Lee, N.J.
The idea for the new research began in conversations between Dr. Kaplitt, a pioneer of brain gene therapy, and Dr. Paul Greengard, of Rockefeller University, a neuroscientist who won a Nobel Prize in 2000 for his work in neurotransmission between brain neurons. In 2006, Dr. Greengard and his Rockefeller colleagues discovered that the p11 gene appears to play a key role in depression. They found p11 protein is needed to bring receptors that bind to the neurotransmitter serotonin to the surface of nerve cells. In the brain, serotonin regulates mood, appetite and sleep, among other functions, and most antidepressants seek to regulate serotonin.
"In the absence of p11, a neuron can produce all the serotonin receptors it needs, but they will not be transported to the cell surface and therefore won't stick out and latch on to the neurotransmitter," says Dr. Kaplitt.
So the researchers decided to disable function of the p11 gene in mice using a virus which would produce an siRNA -- small pieces of double-stranded RNA -- that blocked the gene's expression. Once they showed this could be done, they chose to selectively target p11 expression in the nucleus accumbens brain area because human functional MRI studies at Weill Cornell had shown this area to be particularly affected in depressed patients.
"Focusing exclusively on this area is fairly novel because it had been thought to be mostly involved in behaviors that are tied to addiction," Dr. Kaplitt says.
The mice without p11 all exhibited depression-like behaviors. That prompted Dr. Kaplitt and his team to adapt the gene therapy vehicle they had successfully tested in Parkinson's disease patients in a phase I clinical trial reported in the Lancet in 2007. The therapy uses an inert "smart" virus as a Trojan horse to enter brain cells and deposit a genetic payload into the genome of neurons. These new genes then produce their protein.
To treat Parkinson's disease Dr. Kaplitt used the virus to deliver glutamic acid decarboxylase (GAD), the enzyme that synthesizes the neurotransmitter GABA. In the current study, he inserted the p11 gene into the virus and delivered them to the nucleus accumbens of the p11-free mice. The treatment effectively reversed depression-like behaviors in the mice.
This study also reports that autopsy studies of patients with severe depression revealed significantly reduced levels of the p11 protein in their nucleus accumbens, compared with individuals without depression.
"Together, these studies provide strong evidence that maintaining adequate levels of this particular protein, p11, in this pleasure-reward area of the brain may be central to preventing or treating depression," Dr. Kaplitt says.
The researchers say that not only could the gene therapy used here restore p11, but future research may identify a small molecule to restore p11.
INFORMATION:
ELSE PRESS RELEASES FROM THIS DATE:
Surgical aortic valve replacement should remain the standard treatment for aortic stenosis
2010-10-21
(Boston) - Despite the promising results of the "Placement of Aortic Transcatheter Valves (PARTNER) trial," featured in the Oct. 21 issue of the New England Journal of Medicine, a cardiothoracic surgeon from Boston Medical Center (BMC) believes that surgical aortic-valve replacement should remain the standard treatment of aortic stenosis. In the accompanying editorial, the author argues that Transcatheter aortic-valve implantation (TAVI) should be reserved for patients at inordinately high risk who are not suitable candidates for surgery and who have decreased life expectancy. ...
Energy revolution key to complex life
2010-10-21
The evolution of complex life is strictly dependent on mitochondria, the tiny power stations found in all complex cells, according to a new study by Dr Nick Lane, from UCL (University College London), and Dr William Martin, from the University of Dusseldorf.
"The underlying principles are universal. Energy is vital, even in the realm of evolutionary inventions," said Dr Lane, UCL Department of Genetics, Evolution and Environment. "Even aliens will need mitochondria."
For 70 years scientists have reasoned that evolution of nucleus was the key to complex life. Now, in ...
Star, not so bright
2010-10-21
In a galaxy far away, an exceptionally massive black hole is traveling around a massive star in an unusually tight orbit. Also odd, the star is not as bright as it should be.
Astronomers have puzzled over this X-ray binary system, named M33 X-7, but no one could explain all of its features. Now a Northwestern University research team has.
The researchers have produced a model of the system's evolutionary history and formation that explains all of the system's observational characteristics: the tight orbit, the large masses of the star and black hole, the X-ray luminosity ...
New space research settles years of scientific debate
2010-10-21
New space research published this week (Thursday 21 October) in the journal Nature, has settled decades of scientific debate. Researchers from the University of California (UCLA) and British Antarctic Survey (BAS) have found the final link between electrons trapped in space and the glow of light from the upper atmosphere known as the diffuse aurora. The research will help us understand 'space weather', with benefits for the satellite, power grid and aviation industries, and how space storms affect the Earth's atmosphere from the top down.
Scientists have long understood ...
Clearing the cosmic fog
2010-10-21
A European team of astronomers using ESO's Very Large Telescope (VLT) has measured the distance to the most remote galaxy so far. By carefully analysing the very faint glow of the galaxy they have found that they are seeing it when the Universe was only about 600 million years old (a redshift of 8.6). These are the first confirmed observations of a galaxy whose light is clearing the opaque hydrogen fog that filled the cosmos at this early time. The results will be presented at an online press conference with the scientists on 19 October 2010, and will appear in the 21 October ...
UT MD Anderson scientists show TAp63 suppresses cancer metastasis
2010-10-21
HOUSTON - Long overshadowed by p53, its famous tumor-suppressing sibling, the p63 gene does the tougher, important job of stifling the spread of cancer to other organs, researchers at The University of Texas MD Anderson Cancer Center report in the Oct. 21 issue of Nature.
Not only does a specific form of p63 protein block metastasis, but it does so by activating the enzyme Dicer, which plays a pivotal role in the creation of micro RNAs, tiny bits of RNA that regulate a host of cellular processes.
"p63 is a master regulator of metastasis, an important role in its own ...
Mount Sinai researchers find potential therapeutic target across a range of cancer types
2010-10-21
Researchers from Mount Sinai School of Medicine, in collaboration with investigators of the National Institute of Health and Medical Research (INSERM) of France led by Nicolae Ghinea, PhD, have found a common link among several malignant tumor types in all grades of cancer. This breakthrough may ultimately provide a new diagnostic or therapeutic target to detect cancer early or stop tumor growth. The study is published in the October 21 issue of The New England Journal of Medicine.
The team discovered that a hormone receptor typically found in human reproductive organs ...
New tumor proteins may identify a range of cancers early
2010-10-21
COLUMBUS, Ohio – A new study led by Ohio State University cancer researchers describes a novel cancer-specific protein that is present in a broad range of cancer types and at all stages of tumor development, from premalignant cells to metastatic tumor cells.
If verified, the antigen could serve as a marker for the early detection and treatment of primary and metastatic tumors, and provide a target for the development of anticancer therapies, the researchers say.
In addition, a vaccine designed to target these cancer-cell proteins, called Piwil2-like (PL2L) proteins, ...
New industrial application for revolutionary forensic metal fingerprinting technique
2010-10-21
Groundbreaking research into fingerprint detection developed at the University of Leicester now has an industrial application, thanks to a new invention by the scientist who developed the technique.
Dr John Bond's method of identifying fingerprints on brass bullet-casings, even after they have been wiped clean, was based on the minuscule amounts of corrosion which can be caused by sweat. First announced in 2008, this breakthrough was cited as one of the technologies 'most likely to change the world' by a panel of experts for BBC Focus magazine and was included in Time ...
NTU researchers develop world's smallest on-chip low-pass filter
2010-10-21
A research team from Nanyang Technological University (NTU) has successfully designed the world's smallest on-chip low-pass filter which is 1,000 times smaller than existing off-chip filters.
A low-pass filter is a circuit that allows low-frequency signals to pass through while reducing unwanted high-frequency signals from passing through. Compared to existing off-chip filters, which are discrete and bulky components, on-chip filters occupy a small area on integrated circuit chips, which can be found in portable devices such as mobile phones, laptops, vehicle-mounted ...
LAST 30 PRESS RELEASES:
Insulin resistance is linked to over 30 diseases – and to early death in women, study of people in the UK finds
Innovative semaglutide hydrogel could reduce diabetes shots to once a month
Weight loss could reduce the risk of severe infections in people with diabetes, UK research suggests
Long-term exposure to air pollution and a lack of green space increases the risk of hospitalization for respiratory conditions
Better cardiovascular health in early pregnancy may offset high genetic risk
Artificial intelligence method transforms gene mutation prediction in lung cancer: DeepGEM data releases at IASLC 2024 World Conference on Lung Cancer
Antibody–drug conjugate I-DXd shows clinically meaningful response in patients with extensive-stage small cell lung cancer
IASLC Global Survey on biomarker testing reveals progress and persistent barriers in lung cancer biomarker testing
Research shows pathway to developing predictive biomarkers for immune checkpoint inhibitors
Just how dangerous is Great Salt Lake dust? New research looks for clues
Maroulas appointed Associate Vice Chancellor, Director of AI Tennessee
New chickadee research finds cognitive skills impact lifespan
Cognitive behavioral therapy enhances brain circuits to relieve depression
Terasaki Institute awarded $2.3 Million grant from NIH for organ transplantation research using organs-on-a-chip technology
Atoms on the edge
Postdoc takes multipronged approach to muon detection
Mathematical proof: Five satellites needed for precise navigation
Scalable, multi-functional device lays groundwork for advanced quantum applications
Falling for financial scams? It may signal early Alzheimer’s disease
Integrating MRI and OCT for new insights into brain microstructure
Designing a normative neuroimaging library to support diagnosis of traumatic brain injury
Department of Energy announces $68 million in funding for artificial intelligence for scientific research
DOE, ORNL announce opportunity to define future of high-performance computing
Molecular simulations, supercomputing lead to energy-saving biomaterials breakthrough
Low-impact yoga and exercise found to help older women manage urinary incontinence
Genetic studies reveal new insights into cognitive impairment in schizophrenia
Researcher develops technology to provide cleaner energy and cleaner water
Expect the unexpected: nanoscale silver unveils intrinsic self-healing abilities
nTIDE September 2024 Jobs Report: Gains in employment for people with disabilities appear to level off after reducing gaps with non-disabled workers
Wiley enhances NMR Spectral Library Collection with extensive new databases
[Press-News.org] Gene therapy may be powerful new treatment for major depressionNewYork-Presbyterian/Weill Cornell paper reports that restoring a crucial gene in a tiny area of the brain reverses depression-like behavior in mice; human data back up the promise of such therapy